Literature DB >> 21441118

STAT3 signaling: anticancer strategies and challenges.

Paul A Johnston1, Jennifer R Grandis.   

Abstract

Multiple lines of evidence place STAT3 at a central node in the development, progression, and maintenance of many human tumors, and STAT3 has been validated as an anti-cancer target in several contexts. STAT3 modulates the transcription of a variety of genes involved in the regulation of critical functions, including cell differentiation, proliferation, apoptosis, angiogenesis, metastasis, and immune responses. For many cancers, elevated levels of activated STAT3 have been associated with a poor prognosis. We review approaches that have been pursued to target STAT3, and we highlight some of the promises and challenges associated with developing an anticancer drug that might therapeutically inhibit the STAT3 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21441118      PMCID: PMC3063716          DOI: 10.1124/mi.11.1.4

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  38 in total

Review 1.  G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation.

Authors:  P T Ram; R Iyengar
Journal:  Oncogene       Date:  2001-03-26       Impact factor: 9.867

2.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

3.  New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.

Authors:  Lucy F Chen; Ezra E W Cohen; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

4.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3.

Authors:  Ling Liu; Kevin M McBride; Nancy C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

Review 5.  STAT3 as a central mediator of neoplastic cellular transformation.

Authors:  David A Frank
Journal:  Cancer Lett       Date:  2006-11-28       Impact factor: 8.679

Review 6.  Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis.

Authors:  Corinne M Silva
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

Review 7.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

Review 8.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

9.  Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.

Authors:  James V Alvarez; Heidi Greulich; William R Sellers; Matthew Meyerson; David A Frank
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

Review 10.  STAT-mediated EGFR signaling in cancer.

Authors:  Kelly M Quesnelle; Amanda L Boehm; Jennifer R Grandis
Journal:  J Cell Biochem       Date:  2007-10-01       Impact factor: 4.429

View more
  147 in total

1.  Rap1GAP regulates renal cell carcinoma invasion.

Authors:  Wan-Ju Kim; Zachary Gersey; Yehia Daaka
Journal:  Cancer Lett       Date:  2012-01-20       Impact factor: 8.679

Review 2.  The prognostic value of pSTAT3 in gastric cancer: a meta-analysis.

Authors:  S Yu; G Li; Z Wang; Z Wang; C Chen; S Cai; Y He
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-02       Impact factor: 4.553

3.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

4.  HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel P Camarco; Tong Ying Shun; John S Lazo; Gabriela Mustata Wilson; Lynn O Resnick; Matthew G LaPorte; Peter Wipf; Donna M Huryn; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2015-09       Impact factor: 1.738

5.  Constitutive activation of STAT3 and cyclin D1 overexpression contribute to proliferation, migration and invasion in gastric cancer cells.

Authors:  Jianfei Luo; Ruicheng Yan; Xiaobo He; Jie He
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

6.  E804 induces growth arrest, differentiation and apoptosis of glioblastoma cells by blocking Stat3 signaling.

Authors:  Yanmin Zhang; Zhaoxiao Du; Zirong Zhuang; Yanjun Wang; Fen Wang; Shuai Liu; Han Wang; Hairong Feng; Haoyuan Li; Liyan Wang; Xianghong Zhang; Aijun Hao
Journal:  J Neurooncol       Date:  2015-09-19       Impact factor: 4.130

7.  Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors.

Authors:  Matthew B Minus; Haopei Wang; Jaime O Munoz; Alexandra M Stevens; Alicia E Mangubat-Medina; Michael J Krueger; Wei Liu; Moses M Kasembeli; Julian C Cooper; Mikhail I Kolosov; David J Tweardy; Michele S Redell; Zachary T Ball
Journal:  Org Biomol Chem       Date:  2020-05-06       Impact factor: 3.876

8.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.

Authors:  David Vasquez-Dunddel; Fan Pan; Qi Zeng; Mikhail Gorbounov; Emilia Albesiano; Juan Fu; Richard L Blosser; Ada J Tam; Tullia Bruno; Hao Zhang; Drew Pardoll; Young Kim
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 9.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling.

Authors:  Ronald Bozeman; Erika L Abel; Everardo Macias; Tianyi Cheng; Linda Beltran; John DiGiovanni
Journal:  Mol Carcinog       Date:  2014-01-25       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.